Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

26 September 2023

Generic Drugmaking Firms Fall Short for Poorest Patients

Writing for Bloomberg, Chris Kay covers the launch of the Foundation's first report from its Generic & Biosimilar Medicines programme. The report consists of in-depth profiles of five major manufacturers, assessing them on their efforts to expand access to their products in low- and middle-income countries, and outlining opportunities to make further impact.

Direct links

Read the article

The article focuses on the shortfalls by these companies, pulling out the statistic from the report that only one product, out of the 50 in scope that are produced by the manufacturers assessed, includes a pricing strategy that takes affordability into account.

The article notes that the report provides clear opportunities for companies to ramp up their efforts and make it easier for people living in low- and middle-income countries to get the medicines they need.

Read the Foundation's report on generic and biosimilar medicine manufacturers.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved